Evidence item

The retrospective analysis found longer median survival associated with levetiracetam in DMG, but no survival effect in hemispheric pediatric high-grade glioma. DIRECT_TEXT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 13528

Source: Levetiracetam therapeutically targets GABAergic synapses in diffuse midline glioma · locator {} · excerpt hash sha256:c334e83fb1c26d1a171eea9ca8f07562b33c7d724af1a77c314e10c93a89334d

Exact excerpt

The DMG analysis suggests that patients with DMG (n = 119) who had a history of levetiracetam usage (n = 15 children) exhibited a longer median OS compared to those without levetiracetam usage (n = 104 children) ... median OS of 20.96 months, compared to ... 9.92 months (P = 0.015). ... Analysis ... focused on hemispheric pediatric HGGs revealed no effect ... (n = 40 patients with levetiracetam use, median OS of 24.0 months versus n = 59 ... 22.2 months, P = 0.96).

Linked claims

Claim	Direction	Relevance	Steps	Counted
efe833a9	SUPPORT	DIRECT	0	yes

Audits

None.